Dr. Suzanne M. Cole
Claim this profileUT Southwestern/Simmons Cancer Center-Dallas
Area of expertise
Bladder Cancer
Suzanne M. Cole has run 10 trials for Bladder Cancer. Some of their research focus areas include:
Kidney Cancer
Suzanne M. Cole has run 6 trials for Kidney Cancer. Some of their research focus areas include:
Affiliated Hospitals
UT Southwestern/Simmons Cancer Center-Dallas
UT Southwestern Clinical Center At Richardson/Plano
Clinical Trials Suzanne M. Cole is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting
1 award
Phase 2
16 criteria
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting
2 awards
Phase 3
More about Suzanne M. Cole
Clinical Trial Related
5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Suzanne M. Cole has experience with
- Atezolizumab
- Nivolumab
- Avelumab
- Gemcitabine Hydrochloride
- Ipilimumab
- Cabozantinib S-malate
Breakdown of trials Suzanne M. Cole has run
Bladder Cancer
Kidney Cancer
Urothelial Carcinoma
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Suzanne M. Cole specialize in?
Suzanne M. Cole focuses on Bladder Cancer and Kidney Cancer. In particular, much of their work with Bladder Cancer has involved Stage IV patients, or patients who are Stage II.
Is Suzanne M. Cole currently recruiting for clinical trials?
Yes, Suzanne M. Cole is currently recruiting for 8 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Suzanne M. Cole has studied deeply?
Yes, Suzanne M. Cole has studied treatments such as Atezolizumab, Nivolumab, Avelumab.
What is the best way to schedule an appointment with Suzanne M. Cole?
Apply for one of the trials that Suzanne M. Cole is conducting.
What is the office address of Suzanne M. Cole?
The office of Suzanne M. Cole is located at: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas 75390 United States. This is the address for their practice at the UT Southwestern/Simmons Cancer Center-Dallas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.